Summary
This prediction ended on 13.09.20 with a price of €22.98. With a performance of -8.08%, the BUY prediction for Evotec SE by Mori8 closed slightly in the red. Mori8 has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | -29.167% | -29.167% | -42.373% | -72.443% |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
According to Mori8 what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Fair valuation
High Investments for future growth
Very good company culture
Innovative
Growths faster than the competition
Sustainability is important
Medium risks for its business
Top 10 in its market
Small cyclical dependencies
Very Future proof/growth oriented business model
Cons
Comments by Mori8 for this prediction
In the thread Evotec AG diskutieren
Buy Evotec AG
Evotec erhält über Partnerschaft mit Oxford Zugang zu Biobank QUOD
DJ Evotec erhält über Partnerschaft mit Oxford Zugang zu Biobank QUOD
FRANKFURT (Dow Jones)--Das Wirkstoffunternehmen Evotec hat eine Partnerschaft mit der Universität Oxford geschlossen. In deren Rahmen erhalte Evotec Zugriff auf die Bioproben aus der Biobank Quality in Organ Donation (QUOD), die Forschern Blut-, Urin- und Gewebeproben aus Herz, Lunge, Leber und Niere sowie anonymisierte integrierte Krankenakten von Spendern zur Verfügung stellt, wie das Unternehmen mitteilte.
Die Biobank ist ein gemeinsames Programm eines Konsortiums von akademischen Transplantationszentren und der britischen Gesundheitsbehörde National Health Service Blood and Transplant (NHSBT). Die Proben wurden von QUOD über mehrere Jahre hinweg mit dem Ziel gesammelt, Biomarker zu identifizieren, Verletzungs- und Regenerationsmechanismen zu erklären sowie die Organverwendung und -transplantation zu verbessern